JW Lifescience Corporation

KOSE:A234080 Stock Report

Market Cap: ₩182.6b

JW Lifescience Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for JW Lifescience.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth20.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Nov 24

Solid Earnings Reflect JW Lifescience's (KRX:234080) Strength As A Business

Even though JW Lifescience Corporation's ( KRX:234080 ) recent earnings release was robust, the market didn't seem to...
Analysis Article • Apr 20

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Mar 11

Introducing JW Lifescience (KRX:234080), A Stock That Climbed 36% In The Last Year

There's no doubt that investing in the stock market is a truly brilliant way to build wealth. But if when you choose to...
Analysis Article • Feb 21

What Type Of Shareholders Make Up JW Lifescience Corporation's (KRX:234080) Share Registry?

If you want to know who really controls JW Lifescience Corporation ( KRX:234080 ), then you'll have to look at the...
Analysis Article • Feb 02

Is JW Lifescience Corporation (KRX:234080) A Smart Pick For Income Investors?

Dividend paying stocks like JW Lifescience Corporation ( KRX:234080 ) tend to be popular with investors, and for good...
Analysis Article • Jan 12

We Think JW Lifescience (KRX:234080) Can Manage Its Debt With Ease

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 23

Is It Smart To Buy JW Lifescience Corporation (KRX:234080) Before It Goes Ex-Dividend?

JW Lifescience Corporation ( KRX:234080 ) is about to trade ex-dividend in the next 4 days. You can purchase shares...
Analysis Article • Dec 23

Is JW Lifescience Corporation's (KRX:234080) Recent Performance Tethered To Its Attractive Financial Prospects?

JW Lifescience's (KRX:234080) stock is up by 7.0% over the past three months. Given its impressive performance, we...
Analysis Article • Nov 27

How Much Did JW Lifescience's(KRX:234080) Shareholders Earn From Share Price Movements Over The Last Three Years?

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as JW Lifescience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSE:A234080 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026252,72129,18533,83847,378N/A
12/31/2025257,82928,60627,10440,537N/A
9/30/2025248,29747,58927,66041,124N/A
6/30/2025243,63849,48544,40256,389N/A
3/31/2025235,77544,96237,26049,275N/A
12/31/2024222,47843,98840,44550,690N/A
9/30/2024221,32128,81747,54356,152N/A
6/30/2024214,51026,60916,31124,957N/A
3/31/2024212,20325,61613,04721,285N/A
12/31/2023206,86028,14429,30737,574N/A
9/30/2023203,46622,45412,01918,187N/A
6/30/2023200,05120,72222,88330,907N/A
3/31/2023195,08717,98924,78333,048N/A
12/31/2022188,93114,9615,83514,129N/A
9/30/2022183,11312,13319,86329,549N/A
6/30/2022175,62413,25017,35925,821N/A
3/31/2022171,22612,00013,65724,585N/A
12/31/2021169,81712,91410,92930,165N/A
9/30/2021170,0395,62325,01352,604N/A
6/30/2021174,8239,66821,93649,578N/A
3/31/2021179,65715,90626,09250,741N/A
12/31/2020183,52117,30030,51746,755N/A
9/30/2020183,44927,97113,07020,887N/A
6/30/2020181,52525,08827,50235,216N/A
3/31/2020175,93723,01521,66030,031N/A
12/31/2019170,22121,938N/A24,276N/A
9/30/2019164,79421,366N/A39,036N/A
6/30/2019161,96421,485N/A20,578N/A
3/31/2019156,83318,703N/A30,745N/A
12/31/2018155,23015,821N/A36,130N/A
9/30/2018154,06914,363N/A24,015N/A
6/30/2018151,38813,671N/A23,168N/A
3/31/2018148,33114,997N/A18,137N/A
12/31/2017143,60016,783N/A22,050N/A
9/30/2017139,23416,681N/A18,447N/A
6/30/2017133,22315,922N/A24,366N/A
3/31/2017133,29915,314N/A21,987N/A
12/31/2016132,29015,162N/A16,081N/A
9/30/2016129,09615,416N/A13,542N/A
6/30/2016129,22314,496N/A20,227N/A
3/31/2016127,27214,097N/A22,885N/A
12/31/2015125,95012,864N/A25,897N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A234080's forecast earnings growth is above the savings rate (3.1%).

Earnings vs Market: Insufficient data to determine if A234080's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A234080's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A234080's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A234080's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A234080's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/27 08:55
End of Day Share Price 2026/05/27 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

JW Lifescience Corporation is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tae Young LeeKB Securities Co., Ltd.
Changmin YoonShinhan Investment Corp.